Specifically, blocking CD39 with POM-1 significantly increased the antitumor activation of CTLA-4 mAb in a mouse model of lung metastasis, and showed better efficacy in a CD39-deficient mouse model of tumor transplanted with B16F10 (39). Here, ENTPD1 is linked to neoplasm.